New drug combo takes aim at Hard-to-Treat cancers

NCT ID NCT04443088

Recruiting now Disease control Sponsor: Shenzhen Ionova Life Sciences Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing an experimental drug called INV-1120, either by itself or combined with the immunotherapy pembrolizumab (Keytruda), in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses and check for side effects. About 78 participants will take part across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: INV-1120 (an experimental oral drug) and pembrolizumab (an immunotherapy)
What this could lead to: If this early trial shows safety and hints of tumor shrinkage, it could point toward a new treatment option for advanced cancers like colorectal, breast, or lung cancer.
What could go wrong: This is a very early Phase 1 study with only 78 participants. The drug may not be safe or effective at the doses tested, and side effects are unknown. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer carcinoma metastatic malignant neoplasm neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER CANCER METASTATIC SOLID CARCINOMA SOLID TUMOR, ADULT SOLID TUMOR, UNSPECIFIED, ADULT TUMOR, SOLID

Contacts and locations

Locations

Horizon Oncology Research, LLC,
COMPLETED

Lafayette, Indiana, 47905, United States
START
COMPLETED

San Antonio, Texas, 78229, United States
UT Health
RECRUITING

San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.